NACDS Foundation Announces Research Grant to Study Impact of Pharmacogenomics on Pharmacy Patient Care
The National Association of Chain Drug Stores Foundation announces Manchester University Pharmacy Program as the recipient of a $60,000 grant to translate pharmacogenomics to impact patient care.
— The National Association of Chain Drug Stores (NACDS) Foundation announces Manchester University Pharmacy Program as the recipient of a $60,000 research grant to translate pharmacogenomics to impact patient care.
Working in conjunction with pharmacogenomics research company RxGenomix, the Manchester University Pharmacy Program will use grant funds to develop and launch a pilot program to evaluate the impact of pharmacogenomics on pharmacy patient care. Specifically, the research project will provide pharmacogenomics services in community pharmacies including collection of DNA samples, interpretation of patient results, counseling and collaboration with prescribers to help optimize patient medication regimens.
“Pharmacists clearly have a leading role to play in the appropriate application of pharmacogenomics in patient care. Education of pharmacists to best implement pharmacogenomics services and to educate other healthcare professionals and the public is critical. This study works towards that end,” stated David Kisor, B.S. Pharm.D., professor and chair of Pharmaceutical Sciences at the Manchester University Pharmacy Program.
Pharmacogenomics is the study of harnessing an individual’s genetic make-up to drive preventive and therapeutic care. Annually, there are more than 360 million prescriptions for medications related to pharmacogenomics information. The number of medications with identified genetic influences is expected only to increase as the Food and Drug Administration and the pharmaceutical industry work to incorporate more pharmacogenomic testing in drug development.
“Pharmacogenomics is the next frontier in patient care and patient safety with medication use. Utilizing advanced technologies to harness genetic information can help identify the right treatments that are specific to the patient,” said NACDS Foundation President Kathleen Jaeger. “The science of pharmacogenomics is rapidly evolving and can substantially influence patients’ medication regimens and ultimate health outcomes.
“We are pleased to support this important research project with RxGenomix and the Manchester University Pharmacy Program to employ new innovations in technology to help advance pharmacy patient care,” Jaeger said.